Dennis H. Kraus, William M. Lydiatt, Snehal G. Patel, Brian O'Sullivan, Ronald A. Ghossein, Suresh K. Mukherji, and Jatin P. Shah

#### CHAPTER SUMMARY
##### Cancers Staged Using This Staging System
Malignancies that arise in the epithelial lining of the paranasal sinuses and nasal cavity, with the exception of lymphoma and sarcoma, are staged according to this system.

##### Cancers Not Staged Using This Staging System
<table>
<tr>
<th>These histopathologic types of cancer ...</th>
<th>Are staged according to the classification for ...</th>
<th>And can be found in chapter ...</th>
</tr>
<tr>
<td>Mucosal melanoma of the nasal cavity and paranasal sinuses</td>
<td>Mucosal melanoma of the head and neck</td>
<td>14</td>
</tr>
</table>

##### Summary of Changes
<table>
<tr>
<th>Change</th>
<th>Details of Change</th>
<th>Level of Evidence</th>
</tr>
<tr>
<td>Anatomy - Primary Site(s)</td>
<td>Occult Primary Tumor: Staging of the patient who presents with EBV-unrelated and HPV-unrelated metastatic cervical lymphadenopathy is not included in this chapter.</td>
<td>IV</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>Separate N staging approaches have been described for HPV-related and HPV-unrelated cancers.</td>
<td>II1,2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N)</td>
<td>Separate N category approaches have been described for patients treated without cervical lymph node dissection (clinical N) and patients treated with cervical lymph neck dissection (pathologic N).</td>
<td>II2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N)</td>
<td>Extranodal extension (ENE) is introduced as a descriptor in all HPV-unrelated cancers.</td>
<td>II1</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>ENE in HPV negative cancers: Only clinically and radiographically overt ENE [ENE(+)] should be used for cN.</td>
<td>II1</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>ENE in HPV negative cancers: Any pathologically detected ENE is considered ENE(+) and is used for pN.</td>
<td>II1</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>ENE in HPV-negative cancers: Presence of ENE is designated pN2a for a single ipsilateral node &lt;3 cm and pN3b for all other node(s).</td>
<td>II1</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>Classification of ENE: Clinically overt ENE is classified as ENE, and is considered ENE(+) for cN.</td>
<td>III3</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>Classification of ENE: Pathologically detected ENE is classified as either ENEmi (≤2mm) or ENEma (&gt;2 mm) for data collection purposes only, but both are considered ENE(+) for definition of pN.</td>
<td>III3</td>
</tr>
</table>
To access the AJCC cancer staging forms, please visit www.cancerstaging.org.

<!-- PageFooter="American College of Surgeons 2017 M.B. Amin et al. (eds.), AJCC Cancer Staging Manual, Eighth Edition, DOI 10.1007/978-3-319-40618-3_12" -->
<!-- PageNumber="137" -->
<!-- PageBreak -->